[ad_1]
Patients admitted to the hospital with a mild Covid-19 infection tested positive for Covid-19 on the RTPCR test after applying ivermectin, a seminar reported Monday.
But ICDDR, says B, is the result of small-scale research. Comprehensive research is needed on a wide range of uses.
Dhaka Medical College Hospital, Professor of Medicine and Secretary Member of the Treatment Protocol Committee. Ahmedul Kabir said: “At the moment, it cannot be used for the treatment of Kovid-19 victims. It can be added to the National Guidelines for Clinical Trials. “
ICDDRB Senior Scientist Dr. Dr. presented the main article at the seminar. Wasif Ahmed Khan.
The study was conducted by ICDDRB from June 16 to September 18 at Kurmitola General Hospital, Dhaka Medical College Hospital and Mugda General Hospital.
In the study, 22 of 7 patients received 12 grams of oral ivermectin daily for five days, 23 received doxycycline with a single dose of ivermectin (200 mg on the first day and 100 mg twice daily for 4 days), and 23 received placebo. .
According to the study, the ICDDRB said that in 14 days, only 6 percent of those taking ivermectin were Covid-19 free, meaning they were found to be Covid-19 free in the RTPCR test.
Eighty-one percent of the ivermectin and doxycycline patients and 30 percent of the placebo patients were coronavirus-free.
According to the research report, on the third day of application, only 16 percent of patients who received ivermectin, 3 percent of patients who received ivermectin and doxycycline, and 3 percent of patients who received placebo were left virus free. On the seventh day the fruit was 50 percent, 30 percent and 13 percent.
On December 2, the International Journal of Infectious Diseases, IJID, published the ICDDRB.
The Managing Director of Bezimco Pharmaceuticals Limited, Nazmul Hasan MP, was present as a keynote guest at the seminar.
“We are delighted to be able to assist in the ivermectin clinical trial,” he said. It is an attempt to find profitable solutions in the fight against the Kovid-19 epidemic. We are delighted with the potential results of this study and it will really strengthen our fight against Covid-19 and help prevent many premature deaths. “
Acting Executive Director of ICDDRB and Senior Director of Nutrition and Clinical Services Dr. Tahmid Ahmed.
He said that in low- and middle-income countries like Bangladesh, it is very important to find an affordable and easy-to-use medical system to deal with this epidemic.
“We are seeking help to conduct a larger trial using only ivermectin to help decision makers with Covid-19 treatment.”
He thanked Beximco Pharmaceuticals Limited, the Department of Health, the Department of Drug Administration, the Bangladesh Medical Research Council and the hospitals participating in the study for their support.
Director of Kurmitola General Hospital Brigadier General Dr. Jamil Ahmed, Dr. Bangladesh Medical. Tareq Ahmed, Ayub Khan, Director of the Department of Drug Administration, Rabbur Reza, Executive Director of Beximco Pharmaceuticals were present.
[ad_2]
